 |
PDBsum entry 1ext
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Signalling protein
|
PDB id
|
|
|
|
1ext
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
Structure
4:1251-1262
(1996)
|
|
PubMed id:
|
|
|
|
|
| |
|
Structures of the extracellular domain of the type I tumor necrosis factor receptor.
|
|
J.H.Naismith,
T.Q.Devine,
T.Kohno,
S.R.Sprang.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
BACKGROUND: Tumor necrosis factor (TNF) is a powerful cytokine that is involved
in immune and pro-inflammatory responses. Two TNF receptors that belong to the
cysteine-rich low affinity nerve growth factor receptor family (TNF-R1 and
TNF-R2) are the sole mediators of TNF signalling. Signalling is thought to occur
when a trimer of TNF binds to the extracellular domains of two or three receptor
molecules, which permits aggregation and activation of the cytoplasmic domains.
The complex is then internalized within an endocytic vesicle, whereupon it
dissociates at low pH. Structure of the soluble extracellular domain of the
receptor (sTNF-R1) both in the unliganded and TNF-bound state have previously
been determined. In both instances, the fourth subdomain of the receptor was
found to be partly disordered. In the unliganded state at pH 7.5, the
extracellular domain forms two distinct types of dimer, parallel and
antiparallel; the antiparallel dimer occludes the TNF-binding. RESULTS: We have
determined the structure of sTNF-R1 in two crystal forms in high salt at pH 3.7.
The orthorhombic crystals diffract to 1.85 ånd the entire polypeptide is well
ordered. In contrast, the C-terminal 32 residues are disordered in the hexagonal
crystals. In the orthorhombic form, these residues exhibit a topology and
disulphide connectivity that differs from the other three cysteine-rich domains
in the molecule. In both forms, the interface is considerably more extensive
than that used in complex formation with LTalpha. This 'low pH' dimer is
different from both of the dimers observed in crystals grown at pH 7.5.
CONCLUSIONS: The occurrence of the antiparallel dimers in both low pH crystal
forms suggest that they are not an artefact of crystal packing. Such dimers may
form in the low pH environment of the endosome. Because the dimer contact
surface occludes the TNF-binding site, formation of this dimer would dissociate
the TNF-receptor complex within the endosome. Three of the four cysteine-rich
domains of TNF-R1 are constructed from two distinct structural modules, termed
A1 and B2. The fourth subdomain comprises an A1 module followed by an unusual C2
module. Although the orientation of these modules with respect to each other is
sensitive to crystal packing, ligand binding, pH and ionic strength, the modules
are structurally well conserved between and within the known sTNF-R1 structures.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 1.
Figure 1. The complete structure of the monomer of sTNF-R1. (a)
A stereo diagram of the numbered Cα trace of the sTNF-R1
molecule found at pH 3.7. (b) A ribbon representation of the
structure with disulphide bonds shown as yellow spheres,
prepared with RASTER3D [31]. Subdomains one and three are in red
and subdomains two and four in orange. Figure 1. The
complete structure of the monomer of sTNF-R1. (a) A stereo
diagram of the numbered Cα trace of the sTNF-R1 molecule found
at pH 3.7. (b) A ribbon representation of the structure with
disulphide bonds shown as yellow spheres, prepared with RASTER3D
[[4]31]. Subdomains one and three are in red and subdomains two
and four in orange.
|
 |
Figure 3.
Figure 3. Two orthogonal views of the low pH dimer that is the
asymmetric unit of the P2[1]2[1]2[1] crystal form. Careful
examination of the figure shows that the interaction between
subdomain one and subdomain four is closer at one end of the
dimer than the other. (Figure prepared using RASTER3D [31].) The
color scheme for one monomer is the same as in Figure 1. The
other monomer is colored dark blue (subdomains one and three)
and bright blue (subdomains two and four). Figure 3. Two
orthogonal views of the low pH dimer that is the asymmetric unit
of the P2[1]2[1]2[1] crystal form. Careful examination of the
figure shows that the interaction between subdomain one and
subdomain four is closer at one end of the dimer than the other.
(Figure prepared using RASTER3D [[3]31].) The color scheme for
one monomer is the same as in [4]Figure 1. The other monomer is
colored dark blue (subdomains one and three) and bright blue
(subdomains two and four).
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from Cell Press:
Structure
(1996,
4,
1251-1262)
copyright 1996.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
F.He,
W.Dang,
K.Saito,
S.Watanabe,
N.Kobayashi,
P.Güntert,
T.Kigawa,
A.Tanaka,
Y.Muto,
and
S.Yokoyama
(2009).
Solution structure of the cysteine-rich domain in Fn14, a member of the tumor necrosis factor receptor superfamily.
|
| |
Protein Sci,
18,
650-656.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
Y.Cao,
Z.Wang,
X.Bu,
S.Tang,
Z.Mei,
and
P.Liu
(2009).
A Synthetic Peptide Derived from A1 Module in CRD4 of Human TNF Receptor-1 Inhibits Binding and Proinflammatory Effect of Human TNF-alpha.
|
| |
Inflammation,
32,
139-145.
|
 |
|
|
|
|
 |
Y.Mukai,
T.Nakamura,
Y.Yoshioka,
S.Tsunoda,
H.Kamada,
S.Nakagawa,
Y.Yamagata,
and
Y.Tsutsumi
(2009).
Crystallization and preliminary X-ray analysis of the tumour necrosis factor alpha-tumour necrosis factor receptor type 2 complex.
|
| |
Acta Crystallogr Sect F Struct Biol Cryst Commun,
65,
295-298.
|
 |
|
|
|
|
 |
D.L.Cecil,
and
R.Terkeltaub
(2008).
Transamidation by transglutaminase 2 transforms S100A11 calgranulin into a procatabolic cytokine for chondrocytes.
|
| |
J Immunol,
180,
8378-8385.
|
 |
|
|
|
|
 |
F.K.Chan
(2007).
Three is better than one: pre-ligand receptor assembly in the regulation of TNF receptor signaling.
|
| |
Cytokine,
37,
101-107.
|
 |
|
|
|
|
 |
K.Aoki,
H.Saito,
C.Itzstein,
M.Ishiguro,
T.Shibata,
R.Blanque,
A.H.Mian,
M.Takahashi,
Y.Suzuki,
M.Yoshimatsu,
A.Yamaguchi,
P.Deprez,
P.Mollat,
R.Murali,
K.Ohya,
W.C.Horne,
and
R.Baron
(2006).
A TNF receptor loop peptide mimic blocks RANK ligand-induced signaling, bone resorption, and bone loss.
|
| |
J Clin Invest,
116,
1525-1534.
|
 |
|
|
|
|
 |
L.M.Sedger,
S.R.Osvath,
X.M.Xu,
G.Li,
F.K.Chan,
J.W.Barrett,
and
G.McFadden
(2006).
Poxvirus tumor necrosis factor receptor (TNFR)-like T2 proteins contain a conserved preligand assembly domain that inhibits cellular TNFR1-induced cell death.
|
| |
J Virol,
80,
9300-9309.
|
 |
|
|
|
|
 |
N.Ravet,
S.Rouaghe,
C.Dodé,
J.Bienvenu,
J.Stirnemann,
P.Lévy,
M.Delpech,
and
G.Grateau
(2006).
Clinical significance of P46L and R92Q substitutions in the tumour necrosis factor superfamily 1A gene.
|
| |
Ann Rheum Dis,
65,
1158-1162.
|
 |
|
|
|
|
 |
S.L.Rebelo,
S.E.Bainbridge,
M.R.Amel-Kashipaz,
P.M.Radford,
R.J.Powell,
I.Todd,
and
P.J.Tighe
(2006).
Modeling of tumor necrosis factor receptor superfamily 1A mutants associated with tumor necrosis factor receptor-associated periodic syndrome indicates misfolding consistent with abnormal function.
|
| |
Arthritis Rheum,
54,
2674-2687.
|
 |
|
|
|
|
 |
A.de Parseval,
U.Chatterji,
G.Morris,
P.Sun,
A.J.Olson,
and
J.H.Elder
(2005).
Structural mapping of CD134 residues critical for interaction with feline immunodeficiency virus.
|
| |
Nat Struct Mol Biol,
12,
60-66.
|
 |
|
|
|
|
 |
N.Yan,
and
Y.Shi
(2005).
Mechanisms of apoptosis through structural biology.
|
| |
Annu Rev Cell Dev Biol,
21,
35-56.
|
 |
|
|
|
|
 |
G.Zhang
(2004).
Tumor necrosis factor family ligand-receptor binding.
|
| |
Curr Opin Struct Biol,
14,
154-160.
|
 |
|
|
|
|
 |
H.M.Kim,
K.S.Yu,
M.E.Lee,
D.R.Shin,
Y.S.Kim,
S.G.Paik,
O.J.Yoo,
H.Lee,
and
J.O.Lee
(2003).
Crystal structure of the BAFF-BAFF-R complex and its implications for receptor activation.
|
| |
Nat Struct Biol,
10,
342-348.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
L.Dong,
M.Hülsmeyer,
H.Dürkop,
H.P.Hansen,
J.Schneider-Mergener,
A.Ziegler,
and
B.Uchanska-Ziegler
(2003).
Human CD30: structural implications from epitope mapping and modeling studies.
|
| |
J Mol Recognit,
16,
28-36.
|
 |
|
|
|
|
 |
O.V.Moroz,
G.G.Dodson,
K.S.Wilson,
E.Lukanidin,
and
I.B.Bronstein
(2003).
Multiple structural states of S100A12: A key to its functional diversity.
|
| |
Microsc Res Tech,
60,
581-592.
|
 |
|
|
|
|
 |
R.L.Schweickhardt,
X.Jiang,
L.M.Garone,
and
W.H.Brondyk
(2003).
Structure-expression relationship of tumor necrosis factor receptor mutants that increase expression.
|
| |
J Biol Chem,
278,
28961-28967.
|
 |
|
|
|
|
 |
S.A.Connolly,
D.J.Landsburg,
A.Carfi,
D.C.Wiley,
G.H.Cohen,
and
R.J.Eisenberg
(2003).
Structure-based mutagenesis of herpes simplex virus glycoprotein D defines three critical regions at the gD-HveA/HVEM binding interface.
|
| |
J Virol,
77,
8127-8140.
|
 |
|
|
|
|
 |
A.Berezov,
J.Chen,
Q.Liu,
H.T.Zhang,
M.I.Greene,
and
R.Murali
(2002).
Disabling receptor ensembles with rationally designed interface peptidomimetics.
|
| |
J Biol Chem,
277,
28330-28339.
|
 |
|
|
|
|
 |
B.A.Kerwin,
B.S.Chang,
C.V.Gegg,
M.Gonnelli,
T.Li,
and
G.B.Strambini
(2002).
Interactions between PEG and type I soluble tumor necrosis factor receptor: modulation by pH and by PEGylation at the N terminus.
|
| |
Protein Sci,
11,
1825-1833.
|
 |
|
|
|
|
 |
C.Langevin,
H.Jaaro,
S.Bressanelli,
M.Fainzilber,
and
C.Tuffereau
(2002).
Rabies virus glycoprotein (RVG) is a trimeric ligand for the N-terminal cysteine-rich domain of the mammalian p75 neurotrophin receptor.
|
| |
J Biol Chem,
277,
37655-37662.
|
 |
|
|
|
|
 |
J.L.Bodmer,
P.Schneider,
and
J.Tschopp
(2002).
The molecular architecture of the TNF superfamily.
|
| |
Trends Biochem Sci,
27,
19-26.
|
 |
|
|
|
|
 |
K.M.Hull,
E.Drewe,
I.Aksentijevich,
H.K.Singh,
K.Wong,
E.M.McDermott,
J.Dean,
R.J.Powell,
and
D.L.Kastner
(2002).
The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder.
|
| |
Medicine (Baltimore),
81,
349-368.
|
 |
|
|
|
|
 |
O.V.Moroz,
A.A.Antson,
E.J.Dodson,
H.J.Burrell,
S.J.Grist,
R.M.Lloyd,
N.J.Maitland,
G.G.Dodson,
K.S.Wilson,
E.Lukanidin,
and
I.B.Bronstein
(2002).
The structure of S100A12 in a hexameric form and its proposed role in receptor signalling.
|
| |
Acta Crystallogr D Biol Crystallogr,
58,
407-413.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
S.A.Connolly,
D.J.Landsburg,
A.Carfi,
D.C.Wiley,
R.J.Eisenberg,
and
G.H.Cohen
(2002).
Structure-based analysis of the herpes simplex virus glycoprotein D binding site present on herpesvirus entry mediator HveA (HVEM).
|
| |
J Virol,
76,
10894-10904.
|
 |
|
|
|
|
 |
A.Carfí,
S.H.Willis,
J.C.Whitbeck,
C.Krummenacher,
G.H.Cohen,
R.J.Eisenberg,
and
D.C.Wiley
(2001).
Herpes simplex virus glycoprotein D bound to the human receptor HveA.
|
| |
Mol Cell,
8,
169-179.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
I.Aksentijevich,
J.Galon,
M.Soares,
E.Mansfield,
K.Hull,
H.H.Oh,
R.Goldbach-Mansky,
J.Dean,
B.Athreya,
A.J.Reginato,
M.Henrickson,
B.Pons-Estel,
J.J.O'Shea,
and
D.L.Kastner
(2001).
The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers.
|
| |
Am J Hum Genet,
69,
301-314.
|
 |
|
|
|
|
 |
E.Y.Jones
(2000).
The tumour necrosis factor receptor family: life or death choices.
|
| |
Curr Opin Struct Biol,
10,
644-648.
|
 |
|
|
|
|
 |
F.K.Chan,
H.J.Chun,
L.Zheng,
R.M.Siegel,
K.L.Bui,
and
M.J.Lenardo
(2000).
A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling.
|
| |
Science,
288,
2351-2354.
|
 |
|
|
|
|
 |
F.K.Chan
(2000).
The pre-ligand binding assembly domain: a potential target of inhibition of tumour necrosis factor receptor function.
|
| |
Ann Rheum Dis,
59,
i50-i53.
|
 |
|
|
|
|
 |
H.T.Idriss,
and
J.H.Naismith
(2000).
TNF alpha and the TNF receptor superfamily: structure-function relationship(s).
|
| |
Microsc Res Tech,
50,
184-195.
|
 |
|
|
|
|
 |
K.F.Chan,
M.R.Siegel,
and
J.M.Lenardo
(2000).
Signaling by the TNF receptor superfamily and T cell homeostasis.
|
| |
Immunity,
13,
419-422.
|
 |
|
|
|
|
 |
G.Jiang,
and
T.Hunter
(1999).
Receptor signaling: when dimerization is not enough.
|
| |
Curr Biol,
9,
R568-R571.
|
 |
|
|
|
|
 |
I.A.Wilson,
and
L.K.Jolliffe
(1999).
The structure, organization, activation and plasticity of the erythropoietin receptor.
|
| |
Curr Opin Struct Biol,
9,
696-704.
|
 |
|
|
|
|
 |
I.L.Shamovsky,
G.M.Ross,
R.J.Riopelle,
and
D.F.Weaver
(1999).
The interaction of neurotrophins with the p75NTR common neurotrophin receptor: a comprehensive molecular modeling study.
|
| |
Protein Sci,
8,
2223-2233.
|
 |
|
|
|
|
 |
O.Livnah,
E.A.Stura,
S.A.Middleton,
D.L.Johnson,
L.K.Jolliffe,
and
I.A.Wilson
(1999).
Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation.
|
| |
Science,
283,
987-990.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
R.H.Arch,
and
C.B.Thompson
(1999).
Lymphocyte survival--the struggle against death.
|
| |
Annu Rev Cell Dev Biol,
15,
113-140.
|
 |
|
|
|
|
 |
S.G.Hymowitz,
H.W.Christinger,
G.Fuh,
M.Ultsch,
M.O'Connell,
R.F.Kelley,
A.Ashkenazi,
and
A.M.de Vos
(1999).
Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5.
|
| |
Mol Cell,
4,
563-571.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
S.S.Cha,
M.S.Kim,
Y.H.Choi,
B.J.Sung,
N.K.Shin,
H.C.Shin,
Y.C.Sung,
and
B.H.Oh
(1999).
2.8 A resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity.
|
| |
Immunity,
11,
253-261.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
J.H.Naismith,
and
S.R.Sprang
(1998).
Modularity in the TNF-receptor family.
|
| |
Trends Biochem Sci,
23,
74-79.
|
 |
|
|
|
|
 |
J.Singh,
E.Garber,
H.Van Vlijmen,
M.Karpusas,
Y.M.Hsu,
Z.Zheng,
J.H.Naismith,
and
D.Thomas
(1998).
The role of polar interactions in the molecular recognition of CD40L with its receptor CD40.
|
| |
Protein Sci,
7,
1124-1135.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
');
}
}
 |